Literature DB >> 20360202

Is there a role for consensus guidelines for P. jiroveci pneumonia prophylaxis in immunosuppressed patients with rheumatic diseases?

Lisa K Stamp, Miriam Hurst.   

Abstract

Entities:  

Mesh:

Year:  2010        PMID: 20360202     DOI: 10.3899/jrheum.091426

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  12 in total

1.  A Young Woman With Sudden Urinary Retention and Sensory Deficits.

Authors:  Sarah L Patterson; Kashif Jafri; Jared A Narvid; Mary Margaretten
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-02-18       Impact factor: 4.794

Review 2.  Pneumocystis Pneumonia and the Rheumatologist: Which Patients Are At Risk and How Can PCP Be Prevented?

Authors:  Rachel M Wolfe; James E Peacock
Journal:  Curr Rheumatol Rep       Date:  2017-06       Impact factor: 4.592

Review 3.  Pathological and protective immunity to Pneumocystis infection.

Authors:  Taylor Eddens; Jay K Kolls
Journal:  Semin Immunopathol       Date:  2014-11-25       Impact factor: 9.623

4.  Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs.

Authors:  Gabriela Schmajuk; Kashif Jafri; Michael Evans; Stephen Shiboski; Milena Gianfrancesco; Zara Izadi; Sarah L Patterson; Ishita Aggarwal; Urmimala Sarkar; R Adams Dudley; Jinoos Yazdany
Journal:  Semin Arthritis Rheum       Date:  2018-11-03       Impact factor: 5.532

5.  Pneumocystis jirovecii pneumonia in mycophenolate mofetil-treated patients with connective tissue disease: analysis of 17 cases.

Authors:  Yongfeng Zhang; Yi Zheng
Journal:  Rheumatol Int       Date:  2014-06-20       Impact factor: 2.631

6.  Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis?

Authors:  Emilio Besada; Johannes C Nossent
Journal:  Clin Rheumatol       Date:  2013-06-11       Impact factor: 2.980

7.  Further Lessons in Pneumocystis Pneumonia Prophylaxis.

Authors:  Gabriela Schmajuk; Jinoos Yazdany
Journal:  JAMA Intern Med       Date:  2018-11-01       Impact factor: 44.409

8.  Toxoplasmic encephalitis during mycophenolate mofetil immunotherapy of neuromuscular disease.

Authors:  Danilo R Bernardo; Nizar Chahin
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-01-22

9.  The CD4 Lymphocyte Count is a Better Predictor of Overall Infection Than the Total Lymphocyte Count in ANCA-Associated Vasculitis Under a Corticosteroid and Cyclophosphamide Regimen: A Retrospective Cohort.

Authors:  Yi-Yun Shi; Zhi-Ying Li; Ming-Hui Zhao; Min Chen
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

10.  A case of granulomatosis with polyangiitis complicated by cyclophosphamide toxicity and opportunistic infections: choosing between Scylla and Charybdis.

Authors:  Elena Ernst; Matthias Girndt; Rainer U Pliquett
Journal:  BMC Nephrol       Date:  2014-02-04       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.